Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 20/20 | 0.58 |
| ▸ | HTR2C | P28335 | 2/20 | 0.58 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13757801 | 0.94 | HTR6 (0.60) | HTR6HTR2CADRA2A | |
| Hydrochloric Acid SCHEMBL9958981 | 0.93 | HTR6 (0.59) | HTR6HTR2CADRA2A | |
| SCHEMBL13757741 | 0.90 | HTR6 (0.60) | HTR6HTR2CADRA2A | |
| Hydrochloric Acid SCHEMBL3152645 | 0.90 | HTR6 (0.59) | HTR6HTR2CADRA2A | |
| SCHEMBL1421964 | 0.89 | HTR6 (0.62) | HTR6HTR2CADRA2A | |
| SCHEMBL1421915 | 0.89 | HTR6 (0.62) | HTR6HTR2CADRA2A | |
| SCHEMBL12659638 | 0.82 | HTR6 (0.58) | HTR6HTR2CADRA2A | |
| SCHEMBL1423764 | 0.82 | HTR6 (0.61) | HTR6HTR2CADRA2A | |
| Hydrochloric Acid SCHEMBL1423303 | 0.81 | HTR6 (0.59) | HTR6HTR2CADRA2A | |
| SCHEMBL13757800 | 0.81 | HTR6 (0.61) | HTR6HTR2CADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105657-A1 | Compounds, Process for their Preparation, Intermediates, Pharmaceutical Compositions and their use in the Treatment of 5-HT6 Mediated Disorders such as Alzheimer's Disease, Cognitive Disorders, Cognitive Impairment Associated with Schizophrenia, Obesity and Parkinson's Disease | ASTRAZENECA AB (SE) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105657-A1 | Compounds, Process for their Preparation, Intermediates, Pharmaceutical Compositions and their use in the Treatment of 5-HT6 Mediated Disorders such as Alzheimer's Disease, Cognitive Disorders, Cognitive Impairment Associated with Schizophrenia, Obesity and Parkinson's Disease | HTR6, HTR3B, HTR5A | HTR6 1/4885HTR2C 10/4885ADRA2A 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.